Sonnet BioTherapeutics
SONN
SONN
16 hedge funds and large institutions have $2.63M invested in Sonnet BioTherapeutics in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Holders
16
Holding in Top 10
–
Calls
$305K
Puts
–
Top Buyers
| 1 | +$634K | |
| 2 | +$599K | |
| 3 | +$438K | |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$343K |
| 5 |
AC
Ayrton Capital
Westport,
Connecticut
|
+$276K |
Top Sellers
| 1 | -$20.7K | |
| 2 | -$18K | |
| 3 | -$16K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3.24K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.53K |